Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
Notified -
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-01-27, 18:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2024-10-22, 18:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-02-28, 07:27
Alvotech Announces Webcast of 2022 Full Year Financial
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-02-06, 16:08
Alvotech enters into commercialization agreement with
Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia,...
